Want to see HK:6127 full AI Analyst Report?
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$15.13 - HK$29.98
Previous CloseN/A
Volume546.17K
Average Volume (3M)6.46M
Market Cap
HK$41.84B
Enterprise ValueHK$11.58K
Total Cash (Recent Filing)HK$2.49B
Total Debt (Recent Filing)HK$37.00M
Price to Earnings (P/E)79.5
Beta1.43
Next Earnings
Aug 29, 2026EPS Estimate
0.56Next Dividend Ex-DateN/A
Dividend Yield0.54%
Share Statistics
EPS (TTM)0.66
Shares Outstanding118,995,210
10 Day Avg. Volume2,397,586
30 Day Avg. Volume6,458,364
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.00Price Target Upside8.90% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.74
Revenue Forecast (FY)HK$2.21B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a sizable equity base give the company durable financial flexibility to fund lab investments, absorb downturns, and pursue selective capital projects without heavy refinancing, supporting operational continuity and strategic optionality over months to years.
Service Business ModelA fee-for-service CRO model with both project-based and recurring service arrangements aligns with the long-term structural trend of pharma outsourcing. Recurring lab capacity contracts and repeat client work underpin steadier revenue streams and utilization of expensive lab infrastructure.
Operational RecoveryA recent TTM revenue rebound combined with positive net profitability indicates demand resilience and improved operational execution. This recovery supports near-term cash generation and demonstrates the business can convert project volume into earnings after prior troughs.
Bears Say
Revenue Trend WeaknessA multi-year revenue contraction and negative reported growth signal underlying demand or market-share challenges. Persistent top-line decline erodes scale economics and can limit investment capacity unless the TTM rebound is sustained and broad-based across service lines.
Margin CompressionMaterial gross margin compression versus prior years suggests weaker pricing power or rising input costs. Sustained margin pressure reduces operating leverage, constrains reinvestment and returns, and increases vulnerability of profits to revenue volatility over the medium term.
Volatile Free Cash FlowSharp TTM declines and volatility in free cash flow weaken confidence in cash conversion and capital allocation. Inconsistent cash generation complicates funding for capex, working capital, and shareholder returns without dipping into reserves or needing external financing.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$15.13 and its highest was HK$29.98 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$41.84B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Aug 29, 2026 which is in 17 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Apr 29, 2026. The company reported HK$0.367 earnings per share for the quarter, beating the consensus estimate of HK$0.069 by HK$0.298.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Undervalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.138 which represents an annual dividend yield of 0.54%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.56.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.367 in its last earnings report, beating expectations of HK$0.069. Following the earnings report the stock price went down -1.439%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
122.02%
12-Months-Change
Fundamentals
Return on Equity
0.54%
Trailing 12-Months
Asset Growth
12.65%
Trailing 12-Months
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
6127 Stock 12 Month Forecast
Average Price Target
HK$23.00
▲(8.90% Upside)
Technical Analysis
Genscript Biotech
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―